Saturn V Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$38.8M Sell
160,938
-2,023
-1% -$443K 5.56% 7
2026
Q1
$30.8M Sell
162,961
-85,109
-34% -$14.9M 5.58% 8
2025
Q4
$42.2M Sell
248,070
-52,540
-17% -$8.05M 7.74% 4
2025
Q3
$39.6M Buy
300,610
+93,658
+45% +$11.2M 8.69% 3
2025
Q2
$22M Buy
+206,952
New +$22.5M 8.9% 1

Other funds holding JAZZ

Saturn V Capital Management's JAZZ Position: Q2 2026 in Review

Saturn V Capital Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 1.2% in Q2 2026, selling an estimated $443K and leaving 160,938 shares worth $38.8M. The position accounts for 5.56% of the portfolio, ranked #7.

Saturn V Capital Management first reported a position in JAZZ in Q2 2025 and has held it in 5 quarters since. The position peaked at $42.2M in Q4 2025. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Saturn V Capital Management held 160,938 shares of Jazz Pharmaceuticals worth $38.8M as of Q2 2026.
  • Saturn V Capital Management sold 2,023 Jazz Pharmaceuticals shares in Q2 2026, an estimated $443K.
  • Jazz Pharmaceuticals made up 5.56% of Saturn V Capital Management's portfolio in Q2 2026, its #7 holding.
  • Saturn V Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Saturn V Capital Management's Jazz Pharmaceuticals position peaked at $42.2M in Q4 2025.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.